Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

Katie Kompoliti, C. H. Adler, R. Raman, J. H. Pincus, M. T. Leibowitz, J. J. Ferry, L. Blasucci, J. N. Caviness, S. Leurgans, W. M. Chase, L. C. Yones, E. Tan, P. Carvey, C. G. Goetz

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


The authors studied the pharmacokinetics of levodopa (LD) with and without pramipexole (PPX) in men and postmenopausal women with PD. Patients on stable dose of carbidopa/LD were randomized to receive escalating doses of placebo or PPX over 7 weeks. LD and PPX pharmacokinetics were performed after a single test dose 25/100 of carbidopa/LD, before initiation of PPX or placebo, at 1.5 mg/d and 4.5 mg/d of PPX or placebo. Compared to men, women had greater LD bioavailability. PPX did not alter LD bioavailability, and PPX pharmacokinetics were equivalent in men and women.

Original languageEnglish (US)
Pages (from-to)1418-1422
Number of pages5
Issue number9
StatePublished - May 14 2002

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics'. Together they form a unique fingerprint.

Cite this